NasdaqCM - Delayed Quote • USD
Phio Pharmaceuticals Corp. (PHIO)
At close: April 25 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
10,698.0000
10,698.0000
11,462.0000
13,511.0000
8,793.0000
Operating Income
-10,698.0000
-10,698.0000
-11,462.0000
-13,511.0000
-8,793.0000
Net Non Operating Interest Income Expense
--
--
--
-9.0000
-1.0000
Other Income Expense
-128.0000
-128.0000
-18.0000
224.0000
-1.0000
Pretax Income
-10,826.0000
-10,826.0000
-11,480.0000
-13,287.0000
-8,794.0000
Net Income Common Stockholders
-10,826.0000
-10,826.0000
-11,480.0000
-13,287.0000
-8,794.0000
Diluted NI Available to Com Stockholders
-10,826.0000
-10,826.0000
-11,480.0000
-13,287.0000
-8,794.0000
Basic EPS
-5.20
-5.20
-10.10
-12.43
-23.04
Diluted EPS
-5.20
-5.20
-10.10
-12.43
-23.04
Basic Average Shares
2,083.5690
2,083.5690
1,136.5660
1,069.6610
382.2780
Diluted Average Shares
2,083.5690
2,083.5690
1,136.5660
1,069.6610
382.2780
Total Operating Income as Reported
-10,824.0000
-10,824.0000
-11,462.0000
-13,511.0000
-8,793.0000
Total Expenses
10,698.0000
10,698.0000
11,462.0000
13,511.0000
8,793.0000
Net Income from Continuing & Discontinued Operation
-10,826.0000
-10,826.0000
-11,480.0000
-13,287.0000
-8,794.0000
Normalized Income
-10,700.0000
-10,700.0000
-11,480.0000
-13,287.0000
-8,794.0000
Net Interest Income
--
--
--
-9.0000
-1.0000
EBIT
-10,698.0000
-10,698.0000
-11,462.0000
-13,511.0000
-8,793.0000
EBITDA
-10,514.0000
-10,514.0000
-11,269.0000
-13,319.0000
-8,721.0000
Reconciled Depreciation
184.0000
184.0000
193.0000
192.0000
72.0000
Net Income from Continuing Operation Net Minority Interest
-10,826.0000
-10,826.0000
-11,480.0000
-13,287.0000
-8,794.0000
Total Unusual Items Excluding Goodwill
-126.0000
-126.0000
--
233.0000
--
Total Unusual Items
-126.0000
-126.0000
--
233.0000
--
Normalized EBITDA
-10,388.0000
-10,388.0000
-11,269.0000
-13,319.0000
-8,721.0000
12/31/2020 - 5/10/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NKGN NKGen Biotech, Inc.
1.9800
+15.79%
PCSA Processa Pharmaceuticals, Inc.
2.4300
+50.00%
ADIL Adial Pharmaceuticals, Inc.
1.7300
+1.17%
ABVC ABVC BioPharma, Inc.
1.5900
+7.43%
ASLN ASLAN Pharmaceuticals Limited
0.4480
-4.68%
MLEC Moolec Science SA
1.4200
-2.74%
HOOK HOOKIPA Pharma Inc.
0.8061
-5.16%
SILO Silo Pharma, Inc.
1.8801
+0.01%
PALI Palisade Bio, Inc.
6.23
-1.89%
CYTO Altamira Therapeutics Ltd.
1.6000
+11.11%